

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Broudy et al.

Serial No.: 09/352,466

Filed: July 13, 1999

For: Monoclonal Antibodies to Stem Cell Factor Receptors

Docket No.: A-195CDD



Group Art Unit No.: 1642

Examiner: L. Helms

RECEIVED

1/22/01

JAN 19 2001

TECH CENTER 1600/2400

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTAssistant Commissioner for Patents
Washington, D.C. 20231


Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner.

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.


Respectfully submitted,


Robert B. Winter
Attorney/Agent for Applicants
Registration No.: 34,458
Phone: (805) 447-2425
Date:

Please send all future correspondence to:

U.S. Patent Operations/RBW
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.


Date1/11/01
Signature